FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG23894

Real-time Bid/Ask 10:29:29 22/05/2024 BST
5.46 EUR / 5.63 EUR -4.07% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month-36.90%
1 month-31.76%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
21/05/24 5.78 -9.12%
20/05/24 6.36 +20.00%
17/05/24 5.3 -22.63%
16/05/24 6.85 -0.15%
15/05/24 6.86 +7.36%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 08:06 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG2389
ISINDE000MG23894
Date issued 10/04/2024
Strike 28.04 $
Maturity Unlimited
Parity 1.56 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.52
Lowest since issue 5.17
Spread 0.17
Spread %3.02%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
37.37 USD
Average target price
57.95 USD
Spread / Average Target
+55.07%
Consensus